{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T22:31:05Z","timestamp":1766269865234},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2019,11,28]],"date-time":"2019-11-28T00:00:00Z","timestamp":1574899200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,11,28]],"date-time":"2019-11-28T00:00:00Z","timestamp":1574899200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Urol Rep"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1007\/s11934-019-0945-x","type":"journal-article","created":{"date-parts":[[2019,11,28]],"date-time":"2019-11-28T06:02:54Z","timestamp":1574920974000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["High-grade T1 Urothelial Carcinoma: Where Do We Stand?"],"prefix":"10.1007","volume":"20","author":[{"given":"Wesley","family":"Yip","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akbar","family":"Ashrafi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siamak","family":"Daneshmand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,11,28]]},"reference":[{"issue":"1","key":"945_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21551","volume":"69","author":"RL Siegel","year":"2019","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7\u201334.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"945_CR2","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1002\/cncr.28397","volume":"120","author":"Matthew E. Nielsen","year":"2013","unstructured":"Nielsen ME, Smith AB, Meyer AM, Kuo TM, Tyree S, Kim WY, Milowsky MI, Pruthi RS, Millikan RC. Trends in stage-specific incidence rates for urothelial carcinoma of the bladder in the United States: 1988 to 2006. Cancer. 2014;120(1):86-95.","journal-title":"Cancer"},{"issue":"12","key":"945_CR3","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s11934-018-0850-8","volume":"19","author":"PA Reisz","year":"2018","unstructured":"Reisz PA, Laviana AA, Chang SS. Management of high-grade T1 urothelial carcinoma. Curr Urol Rep. 2018;19(12):103.","journal-title":"Curr Urol Rep"},{"issue":"3","key":"945_CR4","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1111\/bju.13760","volume":"119","author":"SL Woldu","year":"2017","unstructured":"Woldu SL, Bagrodia A, Lotan Y. Guideline of guidelines: non-muscle-invasive bladder cancer. BJU Int. 2017;119(3):371\u201380.","journal-title":"BJU Int"},{"issue":"6","key":"945_CR5","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1111\/bju.14238","volume":"122","author":"EEF van de Putte","year":"2018","unstructured":"van de Putte EEF, Bosschieter J, van der Kwast TH, Bertz S, Denzinger S, Manach Q, et al. The World Health Organization 1973 classification system for grade is an important prognosticator in T1 non-muscle-invasive bladder cancer. BJU Int. 2018;122(6):978\u201385.","journal-title":"BJU Int"},{"issue":"4","key":"945_CR6","doi-asserted-by":"publisher","first-page":"293","DOI":"10.3233\/BLC-170126","volume":"3","author":"N Milbar","year":"2017","unstructured":"Milbar N, Kates M, Chappidi MR, Pederzoli F, Yoshida T, Sankin A, et al. Oncological outcomes of sequential intravesical gemcitabine and docetaxel in patients with non-muscle invasive bladder cancer. Bladder Cancer. 2017;3(4):293\u2013303.","journal-title":"Bladder Cancer"},{"issue":"4","key":"945_CR7","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/j.juro.2016.06.049","volume":"196","author":"SS Chang","year":"2016","unstructured":"Chang SS, Boorjian SA, Chou R, Clark PE, Daneshmand S, Konety BR, et al. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline. J Urol. 2016;196(4):1021\u20139.","journal-title":"J Urol"},{"key":"945_CR8","unstructured":"Babjuk M, Burger M, Comp\u00e9rat EM, Gontero P, Mostafid AH, Palou J, van Rhijn BWG, Roupr\u00eat M, Shariat SF, Sylvester R, Zigeuner R. EAU guidelines on non-muscle-invasive bladder cancer (TaT1 and CIS). In: Non-muscle-invasive bladder cancer. European Association of Urology. 2017. https:\/\/uroweb.org\/guideline\/non-muscle-invasive-bladder-cancer. ."},{"key":"945_CR9","unstructured":"Flaig TW, Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Chang SS, Downs TM, Efstathiou JA, Friedlander T, Greenberg RE, Guru KA, Herr HW, Hoimes C, Inman BA, Jimbo M, Kader AK, Lele SM, Meeks JJ, Michalski J, Montgomery JS, Nandagopal L, Pagliaro LC, Pal SK, Patterson A, Plimack ER, Pohar KS, Porter MP, Preston MA, Sexton WJ, Siefker-Radtke AO, Tward J, Wright JL, Gurski LA, Johnson-Chilla A. Bladder cancer. In: NCCN clinical practice guidelines. National Comprehensive Cancer Network. 2019. https:\/\/www.nccn.org\/professionals\/physician_gls\/PDF\/bladder.pdf. Accessed 27 Jul 2019."},{"issue":"6","key":"945_CR10","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1097\/MOU.0000000000000544","volume":"28","author":"M Abufaraj","year":"2018","unstructured":"Abufaraj M, Mostafid H, Shariat SF, Babjuk M. What to do during Bacillus Calmette-Gu\u00e9rin shortage? Valid strategies based on evidence. Curr Opin Urol. 2018;28(6):570\u20136.","journal-title":"Curr Opin Urol"},{"issue":"4 Pt 1","key":"945_CR11","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1097\/01.ju.0000173919.28835.aa","volume":"174","author":"JA Mart\u00ednez-Pi\u00f1eiro","year":"2005","unstructured":"Mart\u00ednez-Pi\u00f1eiro JA, Mart\u00ednez-Pi\u00f1eiro L, Solsona E, Rodr\u00edguez RH, G\u00f3mez JM, Mart\u00edn MG, et al. Has a 3-fold decreased dose of Bacillus Calmette-Guerin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial. J Urol. 2005;174(4 Pt 1):1242\u20137.","journal-title":"J Urol"},{"issue":"4","key":"945_CR12","doi-asserted-by":"publisher","first-page":"e779","DOI":"10.1016\/j.clgc.2019.04.003","volume":"17","author":"BDB Carneiro","year":"2019","unstructured":"Carneiro BDB, Sanches BCF, Andrade DL, Voris BRI, Reis LO. Moreau strain Bacillus Calmette-Gu\u00e9rin low versus standard dose in the treatment of high-grade T1 bladder cancer: a retrospective observational cohort study. Clin Genitourin Cancer. 2019;17(4):e779\u201383.","journal-title":"Clin Genitourin Cancer."},{"issue":"3","key":"945_CR13","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1097\/MOU.0000000000000595","volume":"29","author":"N Mukherjee","year":"2019","unstructured":"Mukherjee N, Wheeler KM, Svatek RS. Bacillus Calmette-Gu\u00e9rin treatment of bladder cancer: a systematic review and commentary on recent publications. Curr Opin Urol. 2019;29(3):181\u20138.","journal-title":"Curr Opin Urol"},{"issue":"2","key":"945_CR14","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.eururo.2009.04.038","volume":"56","author":"PU Malmstr\u00f6m","year":"2009","unstructured":"Malmstr\u00f6m PU, Sylvester RJ, Crawford DE, Friedrich M, Krege S, Rintala E, et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus Bacillus Calmette-Gu\u00e9rin for non-muscle-invasive bladder cancer. Eur Urol. 2009;56(2):247\u201356.","journal-title":"Eur Urol"},{"issue":"1","key":"945_CR15","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.eururo.2011.04.023","volume":"60","author":"RJ Lammers","year":"2011","unstructured":"Lammers RJ, Witjes JA, Inman BA, Leibovitch I, Laufer M, Nativ O, et al. The role of a combined regimen with intravesical chemotherapy and hyperthermia in the management of non-muscle-invasive bladder cancer: a systematic review. Eur Urol. 2011;60(1):81\u201393.","journal-title":"Eur Urol"},{"issue":"6","key":"945_CR16","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1016\/j.eururo.2016.01.006","volume":"69","author":"TJ Arends","year":"2016","unstructured":"Arends TJ, Nativ O, Maffezzini M, de Cobelli O, Canepa G, Verweij F, et al. Results of a randomised controlled trial comparing intravesical chemohyperthermia with mitomycin C versus Bacillus Calmette-Gu\u00e9rin for adjuvant treatment of patients with intermediate- and high-risk non-muscle-invasive bladder cancer. Eur Urol. 2016;69(6):1046\u201352.","journal-title":"Eur Urol"},{"key":"945_CR17","volume":"1","author":"G Jones","year":"2012","unstructured":"Jones G, Cleves A, Wilt TJ, Mason M, Kynaston HG, Shelley M. Intravesical gemcitabine for non-muscle invasive bladder cancer. Cochrane Database Syst Rev. 2012;1:CD009294.","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"945_CR18","doi-asserted-by":"publisher","first-page":"65","DOI":"10.3233\/BLC-150008","volume":"1","author":"RL Steinberg","year":"2015","unstructured":"Steinberg RL, Thomas LJ, O\u2019Donnell MA, Nepple KG. Sequential intravesical gemcitabine and docetaxel for the salvage treatment of non-muscle invasive bladder cancer. Bladder Cancer. 2015;1(1):65\u201372.","journal-title":"Bladder Cancer."},{"issue":"5","key":"945_CR19","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1016\/j.juro.2016.12.090","volume":"197","author":"R Chou","year":"2017","unstructured":"Chou R, Selph S, Buckley DI, Fu R, Griffin JC, Grusing S, et al. Intravesical therapy for the treatment of nonmuscle invasive bladder cancer: a systematic review and meta-analysis. J Urol. 2017;197(5):1189\u201399.","journal-title":"J Urol"},{"issue":"3","key":"945_CR20","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s00345-009-0402-4","volume":"27","author":"RE Hautmann","year":"2009","unstructured":"Hautmann RE, Volkmer BG, Gust K. Quantification of the survival benefit of early versus deferred cystectomy in high-risk non-muscle invasive bladder cancer (T1 G3). World J Urol. 2009;27(3):347\u201351.","journal-title":"World J Urol"},{"issue":"1","key":"945_CR21","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.eururo.2007.06.030","volume":"53","author":"S Denzinger","year":"2008","unstructured":"Denzinger S, Fritsche HM, Otto W, Blana A, Wieland WF, Burger M. Early versus deferred cystectomy for initial high-risk pT1G3 urothelial carcinoma of the bladder: do risk factors define feasibility of bladder-sparing approach? Eur Urol. 2008;53(1):146\u201352.","journal-title":"Eur Urol"},{"issue":"6","key":"945_CR22","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1159\/000472824","volume":"13","author":"M St\u00f6ckle","year":"1987","unstructured":"St\u00f6ckle M, Alken P, Engelmann U, Jacobi GH, Riedmiller H, Hohenfellner R. Radical cystectomy--often too late? Eur Urol. 1987;13(6):361\u20137.","journal-title":"Eur Urol"},{"issue":"1","key":"945_CR23","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.eururo.2009.08.024","volume":"57","author":"GS Kulkarni","year":"2010","unstructured":"Kulkarni GS, Hakenberg OW, Gschwend JE, Thalmann G, Kassouf W, Kamat A, et al. An updated critical analysis of the treatment strategy for newly diagnosed high-grade T1 (previously T1G3) bladder cancer. Eur Urol. 2010;57(1):60\u201370.","journal-title":"Eur Urol"},{"issue":"2","key":"945_CR24","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.eururo.2009.09.024","volume":"57","author":"HM Fritsche","year":"2010","unstructured":"Fritsche HM, Burger M, Svatek RS, Jeldres C, Karakiewicz PI, Novara G, et al. Characteristics and outcomes of patients with clinical T1 grade 3 urothelial carcinoma treated with radical cystectomy: results from an international cohort. Eur Urol. 2010;57(2):300\u20139.","journal-title":"Eur Urol"},{"issue":"6","key":"945_CR25","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1111\/bju.12245","volume":"113","author":"JT Ark","year":"2014","unstructured":"Ark JT, Keegan KA, Barocas DA, Morgan TM, Resnick MJ, You C, et al. Incidence and predictors of understaging in patients with clinical T1 urothelial carcinoma undergoing radical cystectomy. BJU Int. 2014;113(6):894\u20139.","journal-title":"BJU Int"},{"issue":"4","key":"945_CR26","doi-asserted-by":"publisher","first-page":"251","DOI":"10.3109\/00365599.2011.562235","volume":"45","author":"M May","year":"2011","unstructured":"May M, Bastian PJ, Brookman-May S, Burger M, Bolenz C, Trojan L, et al. Pathological upstaging detected in radical cystectomy procedures is associated with a significantly worse tumour-specific survival rate for patients with clinical T1 urothelial carcinoma of the urinary bladder. Scand J Urol Nephrol. 2011;45(4):251\u20137.","journal-title":"Scand J Urol Nephrol"},{"issue":"6","key":"945_CR27","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1200\/JCO.2014.57.6967","volume":"33","author":"W Martin-Doyle","year":"2015","unstructured":"Martin-Doyle W, Leow JJ, Orsola A, Chang SL, Bellmunt J. Improving selection criteria for early cystectomy in high-grade t1 bladder cancer: a meta-analysis of 15,215 patients. J Clin Oncol. 2015;33(6):643\u201350.","journal-title":"J Clin Oncol"},{"key":"945_CR28","doi-asserted-by":"crossref","unstructured":"D Andrea D, Abufaraj M, Susani M, Ristl R, Foerster B, Kimura S, Mari A, Soria F, Briganti A, Karakiewicz PI, Gust KM, Roupr\u00eat M, Shariat SF. Accurate prediction of progression to muscle-invasive disease in patients with pT1G3 bladder cancer: a clinical decision-making tool. Urol Oncol. 2018;36(5):239.e1\u2013239.e7.","DOI":"10.1016\/j.urolonc.2018.01.018"},{"issue":"1","key":"945_CR29","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.eururo.2014.06.040","volume":"67","author":"P Gontero","year":"2015","unstructured":"Gontero P, Sylvester R, Pisano F, Joniau S, Vander Eeckt K, Serretta V, et al. Prognostic factors and risk groups in T1G3 non-muscle-invasive bladder cancer patients initially treated with Bacillus Calmette-Gu\u00e9rin: results of a retrospective multicenter study of 2451 patients. Eur Urol. 2015;67(1):74\u201382.","journal-title":"Eur Urol."},{"issue":"4","key":"945_CR30","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1016\/j.juro.2014.10.098","volume":"193","author":"JM Gaya","year":"2015","unstructured":"Gaya JM, L\u00f3pez-Mart\u00ednez JM, Karni-Schmidt O, Bonal DM, Algaba F, Palou J, et al. \u0394Np63 expression is a protective factor of progression in clinical high grade T1 bladder cancer. J Urol. 2015;193(4):1144\u201350.","journal-title":"J Urol"},{"key":"945_CR31","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s12957-016-0890-9","volume":"14","author":"J Du","year":"2016","unstructured":"Du J, Wang SH, Yang Q, Chen QQ, Yao X. p53 status correlates with the risk of progression in stage T1 bladder cancer: a meta-analysis. World J Surg Oncol. 2016;14:137.","journal-title":"World J Surg Oncol"},{"key":"945_CR32","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.humpath.2016.06.022","volume":"57","author":"MR Raspollini","year":"2016","unstructured":"Raspollini MR, Luque RJ, Menendez CL, Bollito E, Brunelli M, Martignoni G, et al. T1 high-grade bladder carcinoma outcome: the role of p16, topoisomerase-II\u03b1, survivin, and E-cadherin. Hum Pathol. 2016;57:78\u201384.","journal-title":"Hum Pathol"},{"issue":"4","key":"945_CR33","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.clgc.2018.02.001","volume":"16","author":"HW Kang","year":"2018","unstructured":"Kang HW, Seo SP, Byun YJ, Piao XM, Kim YH, Jeong P, et al. Molecular progression risk score for prediction of muscle invasion in primary T1 high-grade bladder cancer. Clin Genitourin Cancer. 2018;16(4):274\u201380.","journal-title":"Clin Genitourin Cancer"},{"issue":"4","key":"945_CR34","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1007\/s00432-018-2593-9","volume":"144","author":"F Sanguedolce","year":"2018","unstructured":"Sanguedolce F, Cormio A, Massenio P, Pedicillo MC, Cagiano S, Fortunato F, et al. Altered expression of HER-2 and the mismatch repair genes MLH1 and MSH2 predicts the outcome of T1 high-grade bladder cancer. J Cancer Res Clin Oncol. 2018;144(4):637\u201344.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"12","key":"945_CR35","doi-asserted-by":"publisher","first-page":"531.e9","DOI":"10.1016\/j.urolonc.2018.09.007","volume":"36","author":"R Mano","year":"2018","unstructured":"Mano R, Zilber S, Di Natale RG, Kedar D, Lifshitz DA, Yossepowitch O, et al. Heat shock proteins 60 and 70 are associated with long-term outcome of T1-stage high-grade urothelial tumors of the bladder treated with intravesical Bacillus Calmette-Gu\u00e9rin immunotherapy. Urol Oncol. 2018;36(12):531.e9\u2013531.e17.","journal-title":"Urol Oncol"},{"issue":"6","key":"945_CR36","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.3889\/oamjms.2018.165","volume":"6","author":"M Wishahi","year":"2018","unstructured":"Wishahi M, Khalil H, Badawy MH, Elkholy A, Eseily K, Anis S, et al. Upregulation of Twist2 in non-muscle invasive urothelial carcinoma of the bladder correlate with response to treatment and progression. Open Access Maced J Med Sci. 2018;6(6):1017\u201322.","journal-title":"Open Access Maced J Med Sci"},{"issue":"8","key":"945_CR37","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.urolonc.2017.06.043","volume":"35","author":"MR Siddiqui","year":"2017","unstructured":"Siddiqui MR, Grant C, Sanford T, Agarwal PK. Current clinical trials in non-muscle invasive bladder cancer. Urol Oncol. 2017;35(8):516\u201327.","journal-title":"Urol Oncol"}],"container-title":["Current Urology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11934-019-0945-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11934-019-0945-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11934-019-0945-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,27]],"date-time":"2020-11-27T00:49:45Z","timestamp":1606438185000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11934-019-0945-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,28]]},"references-count":37,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["945"],"URL":"https:\/\/doi.org\/10.1007\/s11934-019-0945-x","relation":{},"ISSN":["1527-2737","1534-6285"],"issn-type":[{"value":"1527-2737","type":"print"},{"value":"1534-6285","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,28]]},"assertion":[{"value":"28 November 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Wesley Yip and Akbar Ashrafi each declare no potential conflicts of interest. Siamak Daneshmand is a section editor for <i>Current Urology Reports<\/i>.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"79"}}